NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million

May 30, 2024

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NextCell Pharma AB (publ) (”NextCell” or the “Company”) has prepared an EU Growth prospectus (the “Prospectus”) in connection with the Company’s forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders (the “Rights Issue”), which was resolved by the Board of Directors on 24 April 2024 and approved by the Extraordinary General Meeting on 27 May 2024.

The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company’s website, www.nextcellpharma.com, and Redeye’s website, www.redeye.se, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

Timetable for the Rights Issue

31 May – 11 June 2024 Trading in unit rights on Nasdaq First North Growth Market
31 May – 14 June 2024 Subscription period in the Rights Issue
31 May 2024 – Until the Rights Issue is registered by the Swedish Companies Registration Office Trading in paid subscribed units on Nasdaq First North Growth Market
Around 18 June 2024 Expected day for announcement of the outcome

Advisors

Redeye AB is financial advisor to NextCell in connection with the Rights Issue. Törngren Magnell & Partners Advokatfirma KB is legal advisor to the Company in connection with the Rights Issue.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up.
 

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares, paid subscribed units, unit rights or other securities in NextCell in any jurisdiction. An invitation to eligible persons to subscribe for unit rights in NextCell will only be made through the Prospectus.

The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "USA"), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Korea, South Africa or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law.

This press release does not constitute an offer or invitation to acquire or subscribe for shares or other securities in the USA. No shares, paid subscribed units, unit rights, or other securities issued by the Company (the "Securities") have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws in any other state or jurisdiction in the USA, and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the Rights Issue or the accuracy or reliability of the Prospectus. To assert the contrary is a criminal act in the USA.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.

In the United Kingdom, this document and any other materials in relation to the Securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom's version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom's law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release does not identify, or purport to identify, risks (direct or indirect) that may be associated with an investment in Securities. Any investment decision to acquire or subscribe for Securities in connection with the Rights Issue must be made only on the basis of the Prospectus.

Matters discussed in this press release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements.

Download attachmentRead full press release on Cision (external link)
2019-11-07
Correction: Notice to attend the Annual General Meeting
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject t...
Read moreRead more
2019-11-07
Notice to attend the Annual General Meeting
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and Audit Report will be available three weeks before the Meeting, November 14, on the Company's website, www.nextcellpharma.com. This information is the information that NextCell Pharma AB
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and ...
Read moreRead more
2019-10-31
Year-end report 2018-09-01 - 2019-08-31
Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) · Operating income amounted to SEK 1 964 132 (655 413). · Operating result amounted to SEK -21 450 784 (-14 032 294).                · Earnings per share* amounted to SEK -1.36 (-0.61). · Cash and bank amounted to SEK 20 128 185 (3 115 876). · Solidity** amounted to 85.9 (59.2) %. Fourth quarter (2019-06-01 until 2019-08-31) · Operating income amounted to SEK 551 708 (127 868). · Operating result
Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) · Operating income amounted to SEK 1 964 132 (655 413). · Operating result amounted to SEK -21 450 784 (-14 032 294).            ...
Read moreRead more
2019-10-25
NextCell invests in the Danish Cellaviva operations with a new Copenhagen office
NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office. In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub for the Danish Cellaviva business with the opportunity to host customers, hold training sessions etc. The purpose is also to enable increased exposure and presence for NextCell in the Öresund region. [image]      [image]
NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office. In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub fo...
Read moreRead more
2019-10-01
All patients in ProTrans-Repeat are now treated
NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated
NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been ...
Read moreRead more
2019-09-24
Last patient, last visit completed in the dose escalation part
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial. ProTrans-1 is a two-part phase I / II clinical trial where the phase I part evaluates safety for three doses. All nine patients have now been followed up for 12 months and have left the study. As previously communicated, all 15 patients in the phase II part of ProTrans-1 have been treated and will be followed for 12 months. The second part is randomized,
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial. ProTrans-1 is a two-part phase I / II clinical trial where the p...
Read moreRead more
2019-09-12
Update on the ongoing clinical trials
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial after 12 months follow-up. The ProTrans-Repeat has included 5 out of 18 patients. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat type-1 diabetes. A single dose of ProTrans is given and the patients own ability to produce insulin is compared
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial afte...
Read moreRead more
2019-08-16
NextCell Pharma files another patent application
NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the central nervous system. The application was submitted to the Swedish Patent and Registration Agency on August 15 and is formulated to cover the general production of all types of mesenchymal stem cell products derived from multiple donors and cells selected by the selection algorithm. Furthermore, the
NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the centr...
Read moreRead more